Sunitinib (SU11248) was identified as a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) and beta-type platelet-derived growth factor receptor (PDGFRβ) that also inhibits KIT and FLT3 and therefore decreases cancer cell proliferation and survival, and blocks tumor angiogenesis. Here, PDGFRB is linked to cancer.